EUVIMEDEUVIMED entdecken
Leserbrief

Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility

Jaime L Rubin, James L Kreindler

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.02.014 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Jaime L Rubin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: jaime_rubin@vrtx.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansChloride Channel Agonists

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorChloride Channel Agonists

Autor:innen und Institutionen

  • Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: jaime_rubin@vrtx.com.
  • Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: james_kreindler@vrtx.com.

Zitieren

APA

Rubin, J. L., & Kreindler, J. L. (2024). Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.014

Vancouver

Rubin JL, Kreindler JL. Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.014

BibTeX
@article{Rubin2024,
  author = {Rubin, Jaime L and Kreindler, James L},
  title = {Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.02.014}
}
Kostenlos starten →